Ontology highlight
ABSTRACT:
SUBMITTER: Hanlon A
PROVIDER: S-EPMC7727518 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
Hanlon Ashley A Brander Danielle M DM
Hematology. American Society of Hematology. Education Program 20201201 1
Despite the proven effective approach to targeting the phosphatidylinositol-3-kinase (PI3K) pathway in B-cell malignancies, the approved PI3K inhibitors idelalisib and duvelisib have been less commonly selected for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), given the availability of other more tolerable agents. However, patients with CLL/SLL can experience a disease course that is multiply relapsed, refractory, or intolerant to treatment, and PI3K inhibitors ...[more]